Kynamro

Drug - Kynamro™ [Genezyme Corporation]

October 2013

Therapeutic area - Cardiovascular

Approval criteria

• Patient is 18 years of age or older AND
• Patient has a diagnosis of homozygus familial hypercholesterolemia (HoFH) AND
• Patient is concurrently taking at least one other lipid-lowering medication (statins, fibrates, bile acid sequestrants)

Quantity limit

Dose is 200 mg once weekly as a subcutaneous injection; quantity limit is 4 ml per 34-day supply.

Background information

KYNAMRO™ is an oligonucleotide inhibitor of apolipoprotein B-100 synthesis indicated as an adjunct to lipid-lowering medications and diet to reduce low density lipoprotein-cholesterol (LDL-C), apolipoprotein B (apo B), total cholesterol (TC), and non-high density lipoprotein-cholesterol (non HDL-C) in patients with homozygous familial hypercholesterolemia (HoFH).

Questions?

MHCP Provider Call Center 651-431-2700 or 800-366-5411